Introduction {#s1}
============

The retrovirus XMRV (xenotropic murine leukemia virus-related virus) was initially discovered in human prostate cancer samples [@pone.0036073-Urisman1] and was later found in the blood of a high percentage of patients diagnosed with chronic fatigue syndrome (CFS) [@pone.0036073-Lombardi1], raising concern that XMRV was a new human pathogen. However, the majority of subsequent studies have been unable to detect XMRV in humans with or without prostate cancer [@pone.0036073-Aloia1] or CFS [@pone.0036073-Knox1]. In addition, the XMRV isolates from the early studies were all nearly identical to a virus produced by a commonly used prostate cancer cell line, 22Rv1 [@pone.0036073-Knouf1]--[@pone.0036073-Smith1]. Perhaps XMRV was present in the prostate cancer from which the 22Rv1 cells were derived, but the lack of XMRV sequence diversity was puzzling given the high mutation rate of retroviruses. Recently, the XMRV present in 22Rv1 cells was shown to have arisen during passage of the 22Rv1 prostate cancer cells and their ancestors in nude mice, by a rare recombination event between two endogenous mouse retroviruses, and was not detected in early xenografts of the prostate tumor [@pone.0036073-Paprotka2]. The expected rarity of this event and the lack of sequence diversity in the "human" XMRV isolates [@pone.0036073-Smith1], [@pone.0036073-Hue1] suggest that the human samples were contaminated with the 22Rv1 XMRV or plasmid clones of XMRV.

Currently, a role for XMRV in CFS is largely disproven, and the original paper that found this association has been retracted [@pone.0036073-Alberts1]. In particular, a large collaborative study found that two of the laboratory groups involved in the original research could not reliably detect XMRV in patient samples, and that labs that could reliably detect XMRV did not detect XMRV in patients with CFS or in normal controls [@pone.0036073-Simmons1]. In the case of the association of XMRV with prostate cancer, it is still unclear whether some of the original prostate cancer samples might have contained patient-derived XMRV or other related retroviruses.

Here we have analyzed blood plasma and expressed prostatic secretions (EPS) from prostate cancer patients, some of whom previously tested positive for XMRV [@pone.0036073-Urisman1], [@pone.0036073-Dong1]--[@pone.0036073-Barton1], for the presence of XMRV and related retroviruses by using an assay for infectious retroviruses. In addition, we tested blood plasma for neutralizing antibodies against XMRV that might limit our ability to detect XMRV in plasma, and would indicate an immune response against XMRV in the plasma donor. We find no evidence for XMRV or related retroviruses, or a neutralizing antibody response against XMRV, in any of the patient samples.

Results {#s2}
=======

XMRV Detection Methods {#s2a}
----------------------

To detect infectious XMRV and related retroviruses in patient plasma and EPS samples, we used S^+^L^−^ and marker rescue assays that have been shown to effectively detect XMRV [@pone.0036073-Knouf1]. The S^+^L^−^ assay we used measures the ability of a retrovirus to infect and cause spread of the Moloney murine sarcoma virus present in PG-4 cat cells [@pone.0036073-Haapala1], leading to production of transformed foci in the cell layer. The marker rescue assay was performed using *Mus dunni* tail fibroblasts (dunni cells) transduced with a retroviral vector (LAPSN) that produces human placental alkaline phosphatase (AP). The dunni/LAPSN cells were exposed to test samples, were passaged for a month to allow virus spread, and were assayed for production of the LAPSN vector on naive dunni cells. Dunni cells were chosen for this assay because of their susceptibility to a wide range of murine leukemia viruses [@pone.0036073-Miller1], including XMRV, other xenotropic retroviruses, and polytropic retroviruses of the type previously detected in humans [@pone.0036073-Urisman1], [@pone.0036073-Lombardi1], [@pone.0036073-Lo1]. To detect neutralizing antibodies present in patient plasma samples, we used the S^+^L^−^ assay to quantitate replication-competent XMRV after incubation with the samples, in comparison to XMRV incubated with culture medium as a control. In some experiments, we measured the ability of plasma to neutralize the LAPSN vector packaged in XMRV virions (XMRV-pseudotype LAPSN vector) as a surrogate for direct measurement of XMRV neutralization.

To determine the kinetics of virus spread and the sensitivity of the marker rescue assay, the assay was conducted by exposing dunni/LAPSN cells to 50, 25, 10, 5, 1, or 0 focus-forming units (FFU) of XMRV, as determined by S^+^L^−^ assay. The cells were then assayed weekly for LAPSN production during passage of the cells for a month. LAPSN production was detected at one week following infection with 50 FFU of XMRV, at 2 weeks following infection with 10 and 5 FFU, and at 4 weeks for 1 of 2 plates infected with 1 FFU of XMRV. These results show that the marker rescue assay is approximately as sensitive as the S^+^L^−^ assay for detection of XMRV. However, this marker rescue assay may be more sensitive than the S^+^L^−^ assay for some retroviruses because of the known sensitivity of dunni cells to a wide range of murine retroviruses, while fewer types of murine retroviruses can infect the cat cells used in the S^+^L^−^ assay.

No Evidence for XMRV Infection of Prostate Cancer Patients {#s2b}
----------------------------------------------------------

We first tested whether blood plasma from a set of ten prostate cancer patients, three of whom previously tested positive for XMRV by RT-PCR, contained replication-competent XMRV and/or neutralizing antibodies against XMRV ([Table 1](#pone-0036073-t001){ref-type="table"}). We did not detect XMRV or related retroviruses in any sample by S^+^L^−^ assay. To detect neutralizing antibodies, plasma samples were incubated at 1∶10 and 1∶100 dilutions with XMRV-pseudotype LAPSN vector for 30 min at room temperature, and the remaining LAPSN virus was measured by AP^+^ focus assay. Only one of the ten plasma samples showed weak neutralizing activity (neutralizing titer of 10). This neutralizing activity was eliminated by heat inactivation of the plasma, which inactivates complement, showing that no antibodies were present that could directly block virus infection.

10.1371/journal.pone.0036073.t001

###### Plasma samples from ten patients with prostate cancer do not contain infectious XMRV or related retroviruses and can neutralize XMRV only partially if at all.

![](pone.0036073.t001){#pone-0036073-t001-1}

               AP^+^ foci for indicated plasma dilution(HI  =  heat inactivated plasma)[‡](#nt103){ref-type="table-fn"}                        
  ----------- ---------------------------------------------------------------------------------------------------------- --- ----- ----- ----- ------
  VP124                                                           GA                                                      0   85    161   210    10
  **VP234**                                                       AA                                                      0   365   297   266   \<10
  VP538                                                           AA                                                      0   368   340   224   \<10
  VP627                                                           GG                                                      0   292   256   273   \<10
  VP630                                                           GG                                                      0   320   320   257   \<10
  VP653                                                           GG                                                      0   296   268   222   \<10
  **VP663**                                                       AA                                                      0   380   286   280   \<10
  VP673                                                           GA                                                      0   366   258   244   \<10
  VP683                                                           AA                                                      0   320   250   280   \<10
  **VP693**                                                       GG                                                      0   364   262   304   \<10
  No plasma                                                                                                                   233   233   188  

Patient identifiers shown in bold indicate patients who had previously tested positive for XMRV. See Discussion for details.

Nucleotides at position 1385 of the RNase L coding regions of both patient alleles are shown. A G1385A transition at position 1385 results in a glutamine instead of arginine at amino acid position 462 (R462Q) of RNase L, which has been associated with higher XMRV infection rates in homozygous R462Q patients in some studies [@pone.0036073-Urisman1].

The virus neutralization assay was performed by incubating XMRV-pseudotype LAPSN vector (harvested from human cells infected with XMRV and the LAPSN vector) with plasma samples at the indicated dilutions, or with phosphate-buffered saline as a no plasma control, for 30 min at room temperature. The remaining LAPSN virus was measured by infection of HTX human fibrosarcoma cells and staining for foci of AP^+^ cells two days later. Plasma heat inactivation was performed at 56°C for 30 min. All dilutions were performed using phosphate-buffered saline.

Because of the low to undetectable level of neutralizing antibodies in the first set of 10 patient samples, we conducted additional neutralization assays using undiluted plasma. In addition, we measured neutralization of XMRV virus as opposed to the XMRV-pseudotype LAPSN vector. We did not detect replication-competent XMRV or related retroviruses, by S^+^L^−^ or marker rescue assays, in plasma from any of the 21 patients tested, including four who previously tested positive for XMRV by PCR (see [Table 2](#pone-0036073-t002){ref-type="table"} for patient and sample details). Furthermore, we found little to no XMRV-neutralizing activity in the undiluted plasma samples, even without heat treatment to inactivate complement ([Fig. 1](#pone-0036073-g001){ref-type="fig"}). Sample VP950 showed the highest neutralizing activity (75% neutralization), but heat inactivation of the sample before testing, or diluting the sample 10-fold before testing, abolished the neutralizing activity (data not shown), indicating that this activity is very weak and likely is dependent on complement. The fact that infectious XMRV can persist following incubation with the undiluted plasma samples indicates that infectious XMRV could persist in the blood of these prostate cancer patients, and would be detectable in our assays for replication-competent virus. The apparent lack of a humoral immune response against XMRV suggests that these patients are not infected by XMRV, consistent with our inability to detect virus in these plasma samples.

10.1371/journal.pone.0036073.t002

###### Characteristics of plasma and EPS samples tested for infectious XMRV and related retroviruses.

![](pone.0036073.t002){#pone-0036073-t002-2}

  Patient[\*](#nt104){ref-type="table-fn"}    RNase L genotype[†](#nt105){ref-type="table-fn"}   Sample   Times frozen   Amount tested by S+L− assay (µl)   Amount tested by marker rescue assay (µl)
  ------------------------------------------ -------------------------------------------------- -------- -------------- ---------------------------------- -------------------------------------------
  **VP29**                                                           AA                          Plasma        1                       100                                     100
  **VP35**                                                           AA                          Plasma        1                       100                                     100
  VP124                                                              GA                          Plasma        1                       100                                     100
  **VP234**                                                          AA                          Plasma        1                       100                                     100
                                                                                                 Plasma        2                        80                                     80
  **VP432**                                                          AA                          Plasma        2                       100                                     100
  **VP830**                                                          GA                           EPS          2                        30                                     30
  **VP844**                                                          GG                           EPS          2                        50                                     50
                                                                                                  EPS          3                        12                                     12
  VP847                                                              AA                           EPS          2                        30                                     30
                                                                                                  EPS          3                        20                                     20
  VP875                                                              AA                           EPS          2                        50                                     50
                                                                                                  EPS          3                        10                                     10
                                                                                                 Plasma        1                        50                                     50
  **VP881**                                                          GA                           EPS          2                        30                                     30
  VP882                                                              GA                          Plasma        1                        50                                     50
  VP888                                                              AA                          Plasma        1                        50                                     50
  VP897                                                              AA                          Plasma        1                        50                                     50
  VP898                                                              AA                          Plasma        1                        50                                     50
  VP918                                                              AA                          Plasma        1                        50                                     50
  VP922                                                              AA                          Plasma        1                        50                                     50
  VP924                                                              GG                          Plasma        1                        50                                     50
  VP926                                                              AA                          Plasma        1                       100                                     100
  VP931                                                              AA                          Plasma        1                       100                                     100
  VP934                                                              AA                          Plasma        1                       100                                     100
  VP935                                                              AA                          Plasma        1                       100                                     100
  VP949                                                              AA                          Plasma        1                       100                                     100
  VP950                                                              AA                          Plasma        1                       100                                     100
  VP964                                                              GG                          Plasma        1                       100                                     100
  VP967                                                              AA                          Plasma        1                       100                                     100

Patient identifiers shown in bold indicate patients who had previously tested positive for XMRV. See Discussion for details.

Nucleotides at position 1385 of the RNase L coding regions of both patient alleles are shown. See [Table 1](#pone-0036073-t001){ref-type="table"} footnotes for additional details.

![XMRV neutralization by prostate cancer patient plasma.\
Patient numbers are listed at bottom with asterisks indicating those that had previously tested positive for XMRV (see Discussion for details). The XMRV titer was determined after incubation of a small amount of XMRV with undiluted plasma, or with culture medium as a control, as described in [Materials and Methods](#s4){ref-type="sec"}. Results are shown as the ratio of the XMRV titer after incubation with plasma to that after incubation with culture medium, expressed as a percentage. Note that some values exceed 100%, indicating enhancement of XMRV infection by these plasma samples.](pone.0036073.g001){#pone-0036073-g001}

We next tested EPS fluids obtained from excised prostate glands [@pone.0036073-Hong1] for the presence of XMRV. To test for possible effects of EPS on XMRV infectivity, we added a small amount of XMRV to undiluted EPS from a normal prostate, or to culture medium as a control, and measured the titer of these mixtures by using the S^+^L^−^ assay. Duplicate samples for each mixture gave identical results (XMRV titer of 5×10^6^ FFU/ml), showing that XMRV can survive and be detected in EPS fluid. However, no replication-competent virus was detected in any of 5 EPS samples from prostate cancer patients by S^+^L^−^ or marker rescue assays (see [Table 2](#pone-0036073-t002){ref-type="table"} for sample identifiers and amounts tested). Three of these patients had previously tested positive for XMRV in urine ([Table 2](#pone-0036073-t002){ref-type="table"}) [@pone.0036073-Barton1].

Activation of *M. dunni* Endogenous Retrovirus in Some Marker Rescue Assays {#s2c}
---------------------------------------------------------------------------

We did experience some false positive results with the marker rescue assay. In a few cases we detected LAPSN production following exposure of dunni/LAPSN cells to plasma, but viral interference analysis showed that LAPSN transduction was completely blocked in dunni cells expressing the *M. dunni* endogenous retrovirus (MDEV) [@pone.0036073-Miller2], [@pone.0036073-Bonham1], but was unaffected in dunni cells expressing XMRV (data not shown). MDEV and XMRV use different receptors for cell entry, which are blocked by infection with the cognate retrovirus but are unaffected by infection with the alternate virus [@pone.0036073-Miller1]. To confirm that the positive results were indeed artifactual, we performed a marker rescue assay using DU145/LAPSN cells, and found that all of the apparent false-positive patient samples were indeed negative for replication-competent XMRV (data not shown). Previously, MDEV production from *M. dunni* cells was observed following treatment of the cells with 5-iodo-2′-deoxyuridine or hydrocortisone [@pone.0036073-Miller2], and it appears that substances in the patient samples have a similar ability to activate the normally silent MDEV locus in dunni cells.

Discussion {#s3}
==========

Of the 29 plasma and 5 EPS samples from prostate cancer patients that we tested, none had a detectable level of replication-competent XMRV or related retroviruses. Included were two plasma samples (VP29 and VP35) from patients who tested XMRV positive by viral detection DNA microarray (Virochip) analysis in the original study [@pone.0036073-Urisman1], one plasma sample (VP234) from a patient who tested XMRV positive by RT-PCR of prostate tissue RNA [@pone.0036073-Dong1], one plasma sample (VP693) from a patient who tested XMRV positive by RT-PCR of RNA isolated from EPS [@pone.0036073-Hong1], and one plasma sample (VP432) from a patient who tested positive for infectious XMRV in plasma [@pone.0036073-Ruscetti1]. In particular, note that prostate cancer tissue from patient VP35 was the presumed source of the first full-length clone of XMRV [@pone.0036073-Urisman1]. Also included in our analysis were three EPS samples (VP830, VP844 and VP881) and one plasma sample (VP663) from patients who tested XMRV positive by RT-PCR of RNA isolated from urine [@pone.0036073-Barton1]. The S^+^L^−^ and dunni cell-based marker rescue assays that we used to detect virus are both capable of detecting xenotropic and polytropic retroviruses [@pone.0036073-Knouf1], [@pone.0036073-Miller1] of the types previously reported in prostate cancer and CFS patients [@pone.0036073-Urisman1], [@pone.0036073-Lombardi1], [@pone.0036073-Lo1], as well as amphotropic murine leukemia viruses. In addition, the S^+^L^−^ assay can detect RD114 feline retrovirus, feline leukemia virus types A, B and C, gibbon ape leukemia virus, and *Mus caroli* endogenous retrovirus (McERV) [@pone.0036073-Haapala1], [@pone.0036073-Miller1], [@pone.0036073-Miller3], thus the assays we used could have detected the presence of a broad range of gamma retroviruses.

To determine whether XMRV could persist in blood and to detect possible immune responses against XMRV, we assayed the ability of blood plasma to neutralize XMRV infectivity. We detected only minimal neutralization even under the most stringent condition of incubating a small amount of XMRV with undiluted, non-heat-inactivated plasma. At most, 75% of the XMRV was neutralized after incubation with plasma, suggesting that XMRV shed into the blood would have a long enough half-life to allow detection. Indeed, 7 of 21 plasma samples assayed in this way showed ≤10% neutralization ([Fig. 1](#pone-0036073-g001){ref-type="fig"}), indicating that human plasma has little innate neutralizing activity against XMRV. This result is consistent with a previous study of XMRV neutralization by sera from CFS and normal subjects, which showed 0 to 80% XMRV neutralization by undiluted non-heat-inactivated sera, and no XMRV neutralization by heat-inactivated sera [@pone.0036073-Knox1], but is inconsistent with several other studies that detected relatively high neutralization of XMRV by human plasma or serum, even in those testing negative for XMRV by other criteria [@pone.0036073-Groom1]--[@pone.0036073-Zhou1]. For example, Groom et al. [@pone.0036073-Groom1] found examples of \>50% neutralization of virus bearing XMRV Env proteins by heat-inactivated serum at 1∶40 and 1∶80 dilutions, and most of these positive results were from control subjects without prostate cancer or CFS. However, most of the positive sera also neutralized viruses bearing other Env proteins, including that of vesicular stomatitis virus, showing the neutralizing activity was generally nonspecific. Zhou et al. [@pone.0036073-Zhou1] found ∼30% neutralization of virus bearing XMRV Env by a 1∶80 dilution of heat-inactivated serum, with three sera showing ∼50% neutralization. All other assays performed indicated that all of these subjects were uninfected by XMRV.

Several factors may explain the differences in neutralizing antibody activities: i) heparin present in serum or plasma made from blood collected in heparinized tubes can nonspecifically inhibit virus infectivity, ii) repeated freezing and thawing of samples can inactivate complement resulting in reduced neutralization, iii) specific viral components of the virus used for neutralization studies can affect the results (for example, use of Gag proteins from HIV or other murine retroviruses in combination with XMRV Env [@pone.0036073-Groom1]--[@pone.0036073-Zhou1]), and iv) cellular factors incorporated into virions during production of the virus used for neutralization can affect the result [@pone.0036073-Rother1]--[@pone.0036073-Takefman1]. In our study and the study by Knox et al. [@pone.0036073-Knox1], authentic XMRV produced from the human prostate cancer cell line 22Rv1 was used in the neutralization assays, while the studies of Groom et al. [@pone.0036073-Groom1] and Zhou et al. [@pone.0036073-Zhou1] utilized viruses made with Moloney Gag-Pol proteins and XMRV Env, and were produced by transfection of human 293T cells. Additional antigens present in the latter viruses could account for some of the nonspecific neutralization observed.

In summary, we did not detect replication-competent XMRV in the plasma or EPS fluid from prostate cancer patients, nor did we detect significant levels of neutralizing antibodies in plasma. These data support the conclusion from other studies that XMRV has not entered the human population.

Materials and Methods {#s4}
=====================

Human Subjects {#s4a}
--------------

Blood plasma and expressed prostatic fluid (EPS) samples used in the current study were obtained at the Cleveland Clinic following approval by the Cleveland Clinic Foundation Institutional Review Board. All samples were obtained from subjects with prostate cancer after written informed consent was obtained. Plasma samples were prepared from blood collected in standard EDTA tubes, EPS fluid was obtained by massage of excised prostate glands after prostatectomy, and all samples were stored at −70°C. Many of the plasma samples were frozen and thawed once for analysis, while others were frozen and thawed a limited number of times ([Table 2](#pone-0036073-t002){ref-type="table"}).

Cell Culture {#s4b}
------------

*M. dunni* tail fibroblasts (dunni cells) [@pone.0036073-Lander1], 293 human embryonic kidney cells [@pone.0036073-Graham1], 22Rv1 prostate carcinoma cells (ATCC CRL-2505), HTX cells (an approximately diploid subclone of HT-1080 human fibrosarcoma cells) [@pone.0036073-Knouf1] and DU145 prostate cancer cells [@pone.0036073-Mickey1] were grown in Dulbecco's modified Eagle's medium with 4.5 g/l glucose and 10% fetal bovine serum (FBS). PG-4 feline cells [@pone.0036073-Haapala1] were grown in McCoy's medium with 15% FBS. XMRV virus used in this study was harvested from 22Rv1 cells obtained directly from the ATCC.

S^+^L^−^ and XMRV Neutralization Assays {#s4c}
---------------------------------------

PG-4 cells were seeded at 2.5×10^5^ per 6-cm dish on day 1. On day 2, plasma and EPS samples were thawed and portions of each sample (or culture medium as a no plasma control) were incubated with a small volume of infectious XMRV (harvested from 22Rv1 cells) for 15 to 30 minutes at room temperature, while the other portions of the plasma and EPS samples were kept on ice. Virus-spiked and untreated samples were added to the PG-4 cells in the presence of 4 µg/ml Polybrene. Cells were fed on day 3, and foci were counted on day 4 or 5. In some experiments the plasma was heat-inactivated at 56°C for 30 min before assay for virus neutralization.

Marker Rescue Assay {#s4d}
-------------------

Dunni and DU145 cells containing the LAPSN retroviral vector (dunni/LAPSN and DU145/LAPSN cells) were generated by exposing cells to helper-free LAPSN vector generated from PA317 retrovirus packaging cells [@pone.0036073-Miller4] and then selecting the cells in G418 for 1 week to ensure the presence of the vector in all cells in the populations. The marker rescue assay was performed as follows. Dunni/LAPSN or DU145/LAPSN cells were seeded at 5×10^5^ per 6-cm dish on day 1 and were exposed to test samples (blood plasma or EPS) in the presence of 4 µg/ml Polybrene on day 2. The cells were then passaged for a month at high density (to facilitate virus spread) by trypsinizing and reseeding the cells at a 1∶10 dilution every time the cells became confluent. LAPSN production was then measured by feeding confluent cells, harvesting the medium the next day, removing cells by filtration (0.2 µm-pore-size surfactant-free cellulose acetate filters) or by centrifugation (4,000×g for 15 min), by adding medium samples with 4 µg/ml Polybrene to dunni or 293 cells seeded the day before at 5×10^4^ per well of 12-well plates, and by staining the cells for AP two days later.

Virus Interference Assay {#s4e}
------------------------

Replicating virus detected in the marker rescue assay was subjected to interference analysis using dunni cells chronically infected with either XMRV from 22Rv1 cells or with the *M. dunni* endogenous retrovirus (MDEV) from dunni cells. On day 1 the infected and uninfected dunni cells were seeded in 12-well dishes at 5×10^4^ per well. On day 2, the medium was replaced with 1 ml of medium containing 4 µg of Polybrene and 0.1 ml of medium harvested from the marker rescue assay cells. On day 4, the cells were stained for AP. The MDEV-infected dunni cells are resistant to MDEV but permissive to XMRV while the XMRV-infected dunni cells are resistant to XMRV but permissive to MDEV.
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